The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Roche advances subcutaneous Lunsumio in lymphoma amid competitive CAR-T landscape
Roche's subcutaneous Lunsumio has shown comparable efficacy to its intravenous version in treating follicular lymphoma, with an overall response rate of 76.6% versus 81.1% for IV. The new formulation offers advantages in administration time and safety, with lower rates of adverse events and cytokine release syndrome. Roche is also advancing its bispecific therapies, including trials for Lunsumio in combination with other treatments for diffuse large B-cell lymphoma.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.